The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
To enable company to be future-ready by tapping potential in CDMO space
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Subscribe To Our Newsletter & Stay Updated
